Latest Cryo-Cell International Developments
Advancements in stem cell treatments continue to be made at a rapid pace. Keeping up with those advancements is critical in the cord blood banking industry. We pride ourselves on continuing to be the cord blood banking industry leader.
Cryo-Cell International is the world's first and most highly accredited cord blood bank. Through innovation and dedication to quality, Cryo-Cell International sets the highest standards. Cryo-Cell is a leader in cord blood research and holds more cord blood patents, through its research affiliate, than any other cord blood bank. Cryo-Cell International is the bank of choice for parents and physicians. Keep up with the latest Cryo-Cell News.
Cryo-Cell is awarded the most prestigious quality accreditation
Cryo-Cell International is the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. This accreditation applies to all services and facilities that were inspected by FACT.
Cryo-Cell’s New Cord Blood Processing Method Enables Parents to Obtain Better Cord Blood Units for Their Babies
Cryo-Cell International, Inc., the world’s first cord blood bank, announced today that parents are able to obtain better cord blood units for their babies through a new advanced processing technology. Cryo-Cell becomes the first nationwide private cord blood bank to license the new PrepaCyte CB technology from Pall Corporation.
Cryo-Cell International Affiliate Earns Patent For Processing Umbilical Cord Blood For Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
A patent was awarded to Saneron CCEL Therapeutics, Inc. and the University of South Florida for a method of retrieval, incubation and transplantation of cells derived from umbilical cord blood, which can be used to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, MS and Alzheimer's as well as spinal cord and brain injuries.
Cryo-Cell International Chief Scientific Officer Optimistic That an Effective Treatment May be Found for Disability that Affects 10,000 Children Annually.
Cryo-Cell International Chief Scientific Officer Linda L. Kelley, PhD, expressed optimism that an effective treatment for cerebral palsy (CP) using cord blood stem cells may be on the horizon. The first results of a Phase 2 study are the first to demonstrate efficacy using umbilical cord blood as therapy in a large, placebo-controlled, double-blind study.
Second Stem Cell Expert from Harvard’s Dana-Farber Cancer Institute Joins Cryo-Cell International
Cryo-Cell International announced the appointment of Wayne Green, Ph.D., as director of flow cytometry. Dr. Green is responsible for overseeing the highly specialized method for analyzing and sorting blood cells in Cryo-Cell’s state-of-the art laboratory.
Cryo-Cell International Taps Leader in Stem Cell Therapy to Serve as Chief Scientific Officer
Cryo-Cell International, Inc. announced the appointment of Linda Kelley, Ph.D., as chief scientific officer. Dr. Kelley is responsible for overseeing Cryo-Cell’s state-of-the-art laboratory, translational medicine initiatives and quality assurance program at its stem cell and cord blood banking facility.
Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-Clinical Data Indicating That Cord Blood Stem Cells Slow Progression of ALS
Cryo-Cell International's affiliate, Saneron CCEL Therpeutics releases pre-clinical data indicating that cord blood stem cells slow progression of ALS. Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan.
Cryo-Cell International, Inc. Announces Material Transfer Agreement with Stanford University
Cryo-Cell International and Stanford University announced signing a material transfer agreement to test the efficacy of mesenchymal-like stem cells derived from menstrual blood (MenSCs) in a model of pancreatic islet transplantation for type 1 diabetes treatment.
Cryo-Cell Announces Global Expansion in Latin America
Cryo-Cell International, global industry leader in innovative stem cell solutions, announced today that the Company has executed an exclusive agreement to license Cryo-Cell’s signature U-Cord™ and proprietary Céllecell services in Costa Rica beginning this summer. Read More
Cryo-Cell International Shares Recognized in the Healthcare Services Industry for the Lowest Price to Earnings (P/E) Ratio
Cryo-Cell International, one of the world’s largest and most established family cord blood banks and global industry leader in innovative stem cell solutions, announced today that it was evaluated by SmarTrend as among five companies in the Health Care Services industry with the lowest P/E ratios.
Cryo-Cell Announces Advanced New Service and Exclusive Family Healthcare Protection Plan
Cryo-Cell International announced its plans at the American College of Obstetrics and Gynecology (ACOG) annual meeting to launch an advanced new service named U-Cord Plus®, along with an exclusive family healthcare protection plan designed to provide expectant families with expanded options to potentially extend future healthcare protection.
Cryo-Cell Featured in Article by CBS Phoenix, AZ Affiliate KPHO on Benefits of Menstrual Blood Banking
Cryo-Cell International, one of the world’s largest and most established family cord blood banks and global industry leader in innovative stem cell solutions, announced that the Company was featured in an article by CBS Phoenix, AZ affiliate KPHO titled, “Banking Menstrual Blood Could Save Lives.”
Cryo-Cell Announces Publication of Collective Paper Outlining Potential Benefits of Transplanting Umbilical Cord and Menstrual Blood-Derived Stem Cells
Cryo-Cell International, one of the world’s largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced the publication of a collective paper outlining the potential benefits of transplanting stem cells derived from umbilical cord and menstrual blood cells.